Agents that modulate the interaction of B7-1 polypeptide with PD-L1 and methods of use thereof
View Patent ↗Disclosed are methods for modulating an immune response including a method for inhibiting the interaction between a B7 polypeptide and a PD-1 ligand, the method comprising contacting an immune cell bearing a PD-1 ligand, or an immune cell bearing a B7 polypeptide, with an agent that inhibits the interaction between the PD-1 ligand and the B7 polypeptide. Such agents may be an anti-PD-1 ligand antibody or a small molecule. Also disclosed is a method for modulating an immune response comprising contacting an immune cell bearing the PD-1 ligand, or an immune cell bearing the PD-1 polypeptide, with an agent that inhibits interactions between the PD-1 ligand and the PD-1 polypeptide, without inhibiting interactions between the PD-1 ligand and a B7 polypeptide, to thereby modulate an immune response. The agent may be an anti-PD-1 ligand antibody or a small molecule.
1. A method for inhibiting the interaction between a B7-1 polypeptide and a PD-L1 polypeptide, comprising:
a) contacting an immune cell bearing a PD-L1 polypeptide; or
b) contacting an immune cell bearing a B7-1 polypeptide;
with an agent that inhibits the interaction between the PD-L1 polypeptide and the B7-1 polypeptide.
2. The method of claim 1 , wherein the agent is an anti-PD-L1 antibody.
3. The method of claim 1 , wherein said inhibition of the interaction between the PD-L1 polypeptide and the B7-1 polypeptide provides an inhibitory signal to the immune cell.
4. The method of claim 1 , wherein the inhibition of interaction between the PD-L1 polypeptide and the B7-1 polypeptide allows the binding of the B7-1 polypeptide to CTLA-4.
5. The method of claim 1 , wherein the inhibition of interaction between the PD-L1 polypeptide and the B7-1 polypeptide allows the binding of the B7-1 polypeptide to CD28.
6. The method of claim 1 , wherein said immune cell is a monocyte.
7. The method of claim 1 , wherein said immune cell is a dendritic cell.